Dashboard/SAILIFE

SAILIFE

OVERVALUED

Sai Life Sciences Limited

Pharma · NSE

↓ 197.4% vs fair value

52W Low

₹636

+48.6% from low

52W High

₹1,084

-12.8% from high

News sentiment (4 articles)

2 bull2 neutral0 bear

✦

Analyst Note

2d ago

Sai Life Sciences is significantly overvalued, trading at ₹945 against a fair value of ₹317.8, representing a 203.5% premium with low valuation confidence. While the company demonstrates strong earnings growth of 65.8% year-on-year and improving ROCE at 12.5%, it faces critical headwinds: negative free cash flow of ₹-55 Cr and inflated valuation multiples (PE 60.6, PB 8.9) typical of an expensive pharma sector. Earnings quality concerns and neutral sentiment suggest caution. Best suited for growth-focused investors with high risk tolerance and a long time horizon.

Valuation Gauge

OVERVALUED-197.4% Margin of Safety

OVERVALUEDFAIRLY VALUEDUNDERVALUED

Current Price

₹945

Fair Value

₹318

Fair Value Analysis

₹318

Based on earnings growth potential for Pharma sector companies | Sector-expensive: P/E at 81th percentile vs sector peers. | ROCE improving (latest 16.5%) — capital allocation becoming more efficient. | COVID impact: PAT dropped from ₹73Cr (FY2019) to ₹6Cr (FY2022); recovery incomplete. CAGR uses pre-COVID base.

Low confidence

Growth Valuation

100% weight

₹318

Price vs Market

SAILIFE

Nifty 50

Technical Pulse

Plain English — no jargon

RSI 47.5Neutral

52-week range-11.4% from high

L 886.5H 1,084

20-day avg₹1,000▼ 4%

📍

Price PositionNeutral

Not enough price history to assess trend.

💪

Momentum (RSI)Neutral

RSI is 48 — neutral momentum, neither overbought nor oversold.

📈

Short-term TrendNeutral

Insufficient data for short-term trend.

→Combined Verdict

Trading significantly above fair value. Unless you believe the business has permanently re-rated, the risk-reward is unfavorable here.

Shareholding Pattern

Stock Health Score

Mixed Signals

5.4 / 10

Profitability

5/10

EPS of ₹15.9 — ROE data unavailable for full scoring

Debt & Leverage

10/10

D/E ratio of 0.2x is well within the Pharma sector norm of 0.8x — strong balance sheet

Valuation vs Peers

2/10

P/E of 60.7x trades at a significant premium to Pharma sector median (42x)

Cash Flow

1/10

Negative FCF of ₹-55 Cr — company is consuming more cash than it generates

Earnings Growth

10/10

5yr EPS CAGR of 201.2% is well above the Pharma sector average of 15.3% — strong growth

Dividend

4/10

No dividend — typical for growth-stage companies

Sentiment Trend — Last 30 Days

Historical Returns

Key Ratios & Growth

FCF Yield

-1.1%

Free cash flow / market cap

Operating Cash Flow

₹314 Cr

TTM cash from operations

Key Financials

EPS (TTM)

₹15.9

P/E Ratio

60.7x

P/B Ratio

8.9x

ROE

—

ROCE

12.5%

Debt / Equity

0.18x

Beta

—

Div Yield

—

FCF (Cr)

₹-55 Cr

Revenue (Cr)

₹1,660 Cr

EPS Growth 5Y

201.2%

Mkt Cap (Cr)

₹20,330 Cr

52W High

₹1,084

52W Low

₹636.1

Book Value/Share

₹107.8

Financial History

Period	Revenue	Op Profit	OPM%	PAT	EPS
TTM	₹2.2K Cr	₹612 Cr	28.0%	₹333 Cr	₹15.89
2025-03-31	₹1.7K Cr	₹410 Cr	24.0%	₹170 Cr	₹8.16
2024-03-31	₹1.5K Cr	₹287 Cr	20.0%	₹83 Cr	—
2023-03-31	₹1.2K Cr	₹169 Cr	14.0%	₹10 Cr	—
2022-03-31	₹870 Cr	₹126 Cr	15.0%	₹6 Cr	—
2021-03-31	₹760 Cr	₹167 Cr	22.0%	₹61 Cr	—
2020-03-31	₹726 Cr	₹168 Cr	23.0%	₹76 Cr	—
2019-03-31	₹695 Cr	₹176 Cr	25.0%	₹73 Cr	—

Compounded Growth Rates

Sales Growth

3Y+21.3%

5Y+23.3%

10Y—

Profit Growth

3Y+221.7%

5Y+40.4%

10Y—

EPS Growth

3Y—

5Y—

10Y—

Peer Comparison

Pharma

Stock	Price	Fair Value	MoS%	P/E	ROE	Signal
PAR Par Drugs And Chemicals Limited	₹86	₹469.7	+81.7%	7.3	15.4%	FAIRLY_VALUED
IOLCP IOL Chemicals and Pharmaceuticals Limited	₹79.5	₹237.8	+66.6%	19.6	5.2%	FAIRLY_VALUED
KILITCH Kilitch Drugs (India) Limited	₹132.7	₹321	+58.7%	17.7	9.4%	UNDERVALUED
BALPHARMA Bal Pharma Limited	₹69	₹147.5	+53.2%	12.8	12.6%	FAIRLY_VALUED
ZYDUSLIFE Zydus Lifesciences	₹868	₹1,502.2	+42.2%	17.6	19.9%	UNDERVALUED
NATCOPHARM Natco Pharma	₹1,030	₹1,597	+35.5%	11.8	18.0%	UNDERVALUED
JAGSNPHARM Jagsonpal Pharmaceuticals Limited	₹190.6	₹275.2	+30.7%	30.8	20.1%	UNDERVALUED
LUPIN Lupin	₹2,280	₹3,112	+26.7%	22.4	23.8%	UNDERVALUED

Institutional Activity

Bulk deals, block deals, short selling & delivery volume — NSE data

Insider Trading

Community Pulse

What is Dalal Street saying?

r/IndiaInvestments · r/Dalal_Street_Investments · r/IndianStockMarket

No Reddit mentions found yet for SAILIFE.

StockTwits

What traders are saying right now

StockTwits

No StockTwits activity found for SAILIFE.

Search Interest

Google Trends · India · Last 90 days

Trends

Trend data not yet available — check back soon.

Telegram Channels

ET Markets · CNBC TV18 · Moneycontrol · Zee Business · NDTV Profit

No Telegram mentions found yet for SAILIFE.

14 articles

Sai Life Sciences Ltd is Rated Buy - Markets Mojo

Google News: SAILIFE·1d ago

▲ BULLISH

Stock Picks Today: Sai Life Sciences, ICICI Bank, Bharti Airtel, Dixon Tech And More On Brokerages' Radar - NDTV Profit

Google News: SAILIFE·5d ago

▲ BULLISH

Sai Life Sciences appoints new global PR&D head as senior management leader - The Globe and Mail

Google News: SAILIFE·6d ago

– NEUTRAL

Sai Life Sciences Appoints Dr. John Pavey as Senior Management Personnel Effective April 2026 - scanx.trade

Google News: SAILIFE·6d ago

– NEUTRAL

Sai Life Sciences Closes Trading Window Ahead of FY 2026 Results - TipRanks

Google News: SAILIFE·7d ago

Sai Life Sciences Ltd is Rated Buy - Markets Mojo

Google News: SAILIFE·12d ago

Sai Life Sciences Allots 11,100 Equity Shares Under ESOP 2008 Scheme - scanx.trade

Google News: SAILIFE·13d ago

Sai Life Sciences Receives Income Tax Order Worth INR 4.53 Crore for TDS Non-Deduction - scanx.trade

Google News: SAILIFE·16d ago

Sai Life Sciences Ltd Hits All-Time High at Rs.1035, Marking a Significant Milestone - Markets Mojo

Google News: SAILIFE·19d ago

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 17 March 2026 - Mint

Google News: SAILIFE·20d ago

Sai Life Sciences Ltd is Rated Buy - Markets Mojo

Google News: SAILIFE·23d ago

Stock to buy: Jefferies lists 10 reasons to buy its top CRDMO pick Sai Life Sciences - The Economic Times

Google News: SAILIFE·25d ago

Jefferies names Sai Life Sciences top CRDMO pick, lists 10 reasons to buy - Business Standard

Google News: SAILIFE·25d ago

Stock Picks Today: Titan, ONGC, Bharti Airtel, Sai Life Sciences, IndiGo And More On Brokerages' Radar - NDTV Profit

Google News: SAILIFE·25d ago

Company Documents

Annual reports, concall transcripts & regulatory filings

📄

Annual Reports

Last 10 years of annual reports via Screener.in

↗🎙️

Concall Transcripts

Quarterly earnings call transcripts & investor presentations

↗🏛️

NSE Filings

Board meeting outcomes, shareholding patterns, corporate actions

↗📊

Balance Sheet & Cash Flow

10-year financial statements on Screener.in

↗

Share this Stock

Download card · Share on WhatsApp

Share on WhatsApp, Twitter, or any group — each share brings new users to Veritas Quant